Generic Staxyn Availability

Staxyn is a brand name of vardenafil, approved by the FDA in the following formulation(s):

STAXYN (vardenafil hydrochloride - tablet, orally disintegrating;oral)

Has a generic version of Staxyn been approved?

No. There is currently no therapeutically equivalent version of Staxyn available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Staxyn. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors
    Patent 6,362,178
    Issued: March 26, 2002
    Inventor(s): Ulrich; Niewöhner & Mazen; Es-Sayed & Helmut; Haning & Thomas; Schenke & Karl-Heinz; Schlemmer & Jörg; Keldenich & Erwin; Bischoff & Elisabeth; Perzborn & Klaus; Dembowsky & Peter; Serno & Marc; Nowakowski
    Assignee(s): Bayer Aktiengesellschaft
    The 2-phenyl-substituted imidazotriazinones having short, unbranched alkyl radicals in the 9-position are prepared from the corresponding 2-phenyl-imidazotriazinones by chlorosulphonation and subsequent reaction with the amines. The compounds inhibit cGMP-metabolizing phosphodiesterases and are suitable for use as active compounds in pharmaceuticals, for the treatment of cardiovascular and cerebrovascular disorders and/or disorders of the urogenital system, in particular for the treatment of erectile dysfunction.
    Patent expiration dates:
    • October 31, 2018
      ✓ 
      Patent use: TREATMENT OF ERECTILE DYSFUNCTION
  • 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors
    Patent 7,696,206
    Issued: April 13, 2010
    Inventor(s): Niewöhner; Ulrich & Es-Sayed; Mazen & Haning; Helmut & Schenke; Thomas & Schlemmer; Karl-Heinz & Keldenich; Jorg & Bischoff; Erwin & Perzborn; Elisabeth & Dembowsky; Klaus & Serno; Peter & Nowakowski; Marc
    Assignee(s): Bayer Schering Pharma Aktiengesellschaft
    The application claims a compound of the formula or a salt, a hydrate, or a hydrate of a salt thereof. The compounds inhibit cGMP-metabolizing phosphodiesterases and are suitable for use as active compounds in pharmaceuticals, for the treatment of erectile dysfunction.
    Patent expiration dates:
    • October 31, 2018
      ✓ 
      Patent use: TREATMENT OF ERECTILE DYSFUNCTION
  • Pharmaceutical forms with improved pharmacokinetic properties
    Patent 8,613,950
    Issued: December 24, 2013
    Assignee(s): Bayer Intellectual Property GmbH
    The present application relates to novel drug formulations of vardenafil which dissolve rapidly in the mouth and lead to increased bioavailability and to a plateau-like plasma concentration profile, and to processes for their preparation.
    Patent expiration dates:
    • December 23, 2028
      ✓ 
      Drug product

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
Hide
(web4)